Holen Sie sich die Stockscreener-App
22.80
1.85%
-0.43
Handel nachbörslich:
22.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$23.23
Offen:
$23.42
24-Stunden-Volumen:
2.26M
Relative Volume:
0.76
Marktkapitalisierung:
$2.39B
Einnahmen:
$2.20B
Nettoeinkommen (Verlust:
$-842.79M
KGV:
-2.702
EPS:
-8.4382
Netto-Cashflow:
$-332.39M
1W Leistung:
+11.33%
1M Leistung:
+36.45%
6M Leistung:
-1.98%
1J Leistung:
-58.11%
1-Tages-Spanne:
$22.71
$23.84
1-Wochen-Bereich:
$20.72
$23.84
52-Wochen-Spanne:
$10.41
$64.80
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
22.80 | 2.44B | 2.20B | -842.79M | -332.39M | -8.4382 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2025-12-09 | Eingeleitet | Wedbush | Outperform |
| 2025-11-05 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Income Plays: What is the PEG ratio of Sarepta Therapeutics Inc2026 PreEarnings & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Sarepta Therapeutics (SRPT) Is Up 16.3% After Early siRNA Muscle Data Validates Avß6 Platform - Sahm
Aberdeen Group Boosts Stake in Sarepta Therapeutics - National Today
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report? - MSN
The Precedent: Federal Circuit Upholds Gene Therapy Host Cell Claims Under 35 U.S.C. § 101 in Regenxbio Inc., Et Al. v. Sarepta Therapeutics, Inc., Et Al. - JD Supra
SG Americas Securities Trims Sarepta Therapeutics Stake - National Today
SG Americas Securities LLC Lowers Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta gets New Zealand approval for Huntington’s disease trial - Investing.com
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - gurufocus.com
Wealth Enhancement Advisory Services LLC Acquires 62,981 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics, Inc. (SRPT) Stock forecasts - Yahoo Finance UK
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo! Finance Canada
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - finance.yahoo.com
Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Sarepta plans FDA filings seeking full approval for two DMD therapies - msn.com
Trend Review: How volatile is Sarepta Therapeutics Inc stock2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - msn.com
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s 2026 Performance - Yahoo Finance
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector - MSN
Mirador Capital Partners Invests $3M in Sarepta Therapeutics - National Today
Mirador Capital Partners LP Invests $3.01 Million in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Massachusetts Biotech Co. Finds High-Potential Muscle Treatment Breakthrough - Streetwise Reports
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Sarepta (SRPT) skyrockets 35% on Morgan Stanley PT hike, stellar trial results - msn.com
Gene Therapy And US Patent Eligibility Update: REGENXBIO, Inc. v. Sarepta Therapeutics, Inc. - MarketScreener
Sarepta Therapeutics Inc (SRPT) Stock Price & 30 Year Financial Data - gurufocus.com
Why has Sarepta Therapeutics (SRPT) risen by 24.2% following its most recent earnings announcement? - Bitget
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday? - Benzinga
Vanguard realigns reporting; reports 0 shares of Sarepta (SRPT) - Stock Titan
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
(SRPT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Tranche Update on Sarepta Therapeutics, Inc.'s Equity Buyback Plan announced on February 26, 2025. - marketscreener.com
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 8%Here's What Happened - MarketBeat
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
SRPT Stock Surges on Promising Early Results From siRNA Programs - The Globe and Mail
Sarepta TherapeuticsIt's Too Early To Get Excited About siRNA Data (NASDAQ:SRPT) - Seeking Alpha
SRPT: Citigroup Raises Price Target Amid Maintained 'Sell' Ratin - GuruFocus
Sarepta Therapeutics Is Maintained at Sell by Citigroup - Moomoo
Sarepta Therapeutics (NASDAQ:SRPT) Given New $13.00 Price Target at Citigroup - MarketBeat
Deutsche Bank Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Raises Target Price to $14 - Moomoo
Deutsche Bank Adjusts Price Target for Sarepta (SRPT) Amid Stock Rally - GuruFocus
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $35 - Moomoo
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Sarepta Therapeutics (SRPT) Retains 'Underperform' Rating by Nee - gurufocus.com
Sarepta Therapeutics (NASDAQ:SRPT) Earns Underperform Rating from Needham & Company LLC - marketbeat.com
Which Is a Better Investment, Apellis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. Stock? - AAII.com
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):